Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656676 | 0.88 | MEN1 (0.68) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3789796 | 0.86 | ALDH1A1 (0.64) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL17707775 | 0.85 | TSHR (0.53) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL17707777 | 0.85 | TSHR (0.53) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL17707781 | 0.85 | TSHR (0.53) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL3785486 | 0.85 | TSHR (0.53) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL23294948 | 0.84 | TSHR (0.51) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL29588719 | 0.84 | TSHR (0.51) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL29220976 | 0.82 | MAPT (0.50) | TSHRMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL30954344 | 0.82 | MAPT (0.50) | TSHRMAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300499-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | HOVIONE SCIENTIA LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11059021-B2 | Process for the preparation of intermediates useful in the preparation of non-ionic contrast agents | HOVIONE SCIENTIA LIMITED (IE) | 2021-07-13 | — | — | US | disclosed |
| US-20180169607-A1 | Process for the Preparation of Intermediates Useful in the Preparation of Non-ionic Contrast Agents | HOVIONE SCIENTIA LIMITED (IE) | 2018-06-21 | — | — | US | disclosed |
| EP-3300499-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | Hovione Scientia Limited (IE) | 2018-04-04 | — | — | EP | disclosed |
| WO-2016193740-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PREPARATION OF NON-IONIC CONTRAST AGENTS | HOVIONE SCIENTIA LIMITED (IE) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059021-B2 | Process for the preparation of intermediates useful in the preparation of non-ionic contrast agents | PPIP5K2, IPO4, ITPA | TSHR 2482/4885MAPT 4445/4885MEN1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.